Alcoholism & Drug Abuse Weekly June 29, 2026 Alison Knopf
The Michigan Society of Addiction Medicine (MiSAM) has written a letter to the Michigan legislature opposing bill HB 6020, which would use opioid settlement funds to expand research into ibogaine.
Journal of Pharmaceutical and Biomedical Analysis June 24, 2026 Scot Mcintosh, Isabella Maldonado, Nickalus C Smith et al.
Iboga alkaloids, including ibogaine, its primary metabolite noribogaine, and the naturally occurring congener ibogamine, have shown promise for the treatment of substance use and other neuropsychiatric disorders but are limited by cardiotoxic effects. Safer synthetic analogs, such as oxa-noribogaine, are under active development; however, validated analytical methods for quantifying these...
Research Square June 17, 2026 Martijn Arns, Kenneth Shinozuka, Joseph P Barsuglia
Abstract Ibogaine has shown early therapeutic promise for substance use disorders (SUD) and post-traumatic stress disorder in veterans, but concerns about treatment-associated cardiac arrhythmia and death have constrained clinical development. Whether this risk is uniform across indications or concentrated in specific populations is unknown. We conducted a retrospective multisite study of...
Zenodo (CERN European Organization for Nuclear Research) June 12, 2026 Saeid Ghiasi
DEFENSIVE PUBLICATION NOTICE This document is published as a defensive publication to establishprior art and prevent any party from obtaining patent exclusivityover the concepts, methods, architectures, and applicationsdescribed herein. By timestamping this work on Zenodo (aCERN-operated open-access repository), the authors establish animmutable priority date. This work is released under...
Frontiers in Pharmacology June 3, 2026 Burton J. Tabaac, Robin Carhart-Harris, Teresa Yung
Background: Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments often provide limited relief, emerging research explores alternative therapeutic interventions, including...
DELOS Desarrollo Local Sostenible June 3, 2026 Ana Lara Mendonça, Déborah Rezende, Gabriela Alves et al.
A ibogaína é um alcaloide indólico extraído da Tabernanthe iboga, investigado por seu possível papel na redução de sintomas de abstinência, fissura e recaída em transtornos por uso de substâncias. Este estudo teve como objetivo analisar, por meio de revisão de literatura, as evidências científicas sobre eficácia, segurança, mecanismos farmacológicos e implicações ético-regulatórias do uso da...